Asset Details
Do you wish to reserve the book?
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Do you wish to request the book?
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
2015
Overview
Background/aims Real-life anti-vascular endothelial growth factor (VEGF) therapy use in patients with wet age-related macular degeneration (wAMD) was assessed in a retrospective, observational study in Canada, France, Germany, Ireland, Italy, the Netherlands, UK and Venezuela. Methods Medical records of patients with wAMD, who started ranibizumab treatment between 1 January 2009 and 31 August 2009, were evaluated. Data were collected until the end of treatment and/or monitoring or until 31 August 2011. Results 2227 patients who received ≥1 anti-VEGF injection with a baseline visual acuity assessment and ≥1 postbaseline visual acuity assessment for the treated eye were evaluated. Visual acuity improved until about day 120; thereafter, visual acuity gains were not maintained. Mean change in visual acuity score from baseline to years 1 and 2 was +2.4 and +0.6 letters, respectively. Patients received a mean of 5.0 and 2.2 injections in the first and second year, respectively. There were substantial differences in visual outcomes and injection frequency between countries. More frequent visits and injections were associated with greater improvements in visual acuity. Conclusions In clinical practice, fewer injections are administered than in clinical trials. Anti-VEGF treatment resulted in an initial improvement in visual acuity; however, this was not maintained over time. Trial registration number NCT01447043.
Publisher
BMJ Publishing Group LTD,BMJ Publishing Group
Subject
/ Aged
/ Angiogenesis Inhibitors - therapeutic use
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Canada
/ Europe
/ Female
/ Humans
/ Letters
/ Male
/ Studies
/ Tomography, Optical Coherence
/ Vascular endothelial growth factor
/ Vascular Endothelial Growth Factor A - antagonists & inhibitors
